$LH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LABORATORY CORP OF AMERICA HOLDINGS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in LABORATORY CORP OF AMERICA HOLDINGS. Get notifications about new insider transactions in LABORATORY CORP OF AMERICA HOLDINGS for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 10 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Sell | S | 276.55 | 2,500 | 691,375 | 7,844 | 10.3 K to 7.8 K (-24.17 %) |
| May 05 2021 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | M | 98.49 | 2,600 | 256,074 | 0 | |
| May 05 2021 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Sell | S | 269.16 | 2,600 | 699,803 | 15,569 | 18.2 K to 15.6 K (-14.31 %) |
| May 05 2021 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Buy | M | 98.49 | 2,600 | 256,074 | 18,169 | 15.6 K to 18.2 K (+16.70 %) |
| Apr 06 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 1,010 | 0 | 6,781 | |
| Apr 06 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 252.67 | 452 | 114,207 | 10,344 | 10.8 K to 10.3 K (-4.19 %) |
| Apr 06 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 1,010 | 0 | 10,796 | 9.8 K to 10.8 K (+10.32 %) |
| Apr 01 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 251.88 | 667 | 168,004 | 5,006 | 5.7 K to 5 K (-11.76 %) |
| Apr 01 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 251.88 | 812 | 204,527 | 5,237 | 6 K to 5.2 K (-13.42 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 251.58 | 3,595 | 904,430 | 37,433 | 41 K to 37.4 K (-8.76 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Grant | A | 0.00 | 8,042 | 0 | 41,028 | 33 K to 41 K (+24.38 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Payment of Exercise | F | 251.58 | 1,079 | 271,455 | 14,186 | 15.3 K to 14.2 K (-7.07 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Grant | A | 0.00 | 2,413 | 0 | 15,265 | 12.9 K to 15.3 K (+18.78 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 251.58 | 1,079 | 271,455 | 8,001 | 9.1 K to 8 K (-11.88 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Grant | A | 0.00 | 2,413 | 0 | 9,080 | 6.7 K to 9.1 K (+36.19 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 251.58 | 790 | 198,748 | 9,786 | 10.6 K to 9.8 K (-7.47 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Grant | A | 0.00 | 2,104 | 0 | 10,576 | 8.5 K to 10.6 K (+24.83 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 251.58 | 1,079 | 271,455 | 5,673 | 6.8 K to 5.7 K (-15.98 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Grant | A | 0.00 | 2,413 | 0 | 6,752 | 4.3 K to 6.8 K (+55.61 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Payment of Exercise | F | 251.58 | 687 | 172,835 | 6,049 | 6.7 K to 6 K (-10.20 %) |
| Mar 30 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Grant | A | 0.00 | 2,310 | 0 | 6,736 | 4.4 K to 6.7 K (+52.19 %) |
| Mar 29 2021 | LH | LABORATORY CORP OF ... | Wengel Kathryn E | Director | Option Exercise | A | 0.00 | 603 | 0 | 603 | |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 182.51 | 633 | 115,529 | 1,267 | |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 146.59 | 1,533 | 224,722 | 767 | |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 0.00 | 680 | 0 | 1,667 | |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 0.00 | 187 | 0 | 2,347 | |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 182.51 | 633 | 115,529 | 976 | 343 to 976 (+184.55 %) |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Sell | S | 241.52 | 2,317 | 559,589 | 343 | 2.7 K to 343 (-87.11 %) |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 146.59 | 1,533 | 224,722 | 2,660 | 1.1 K to 2.7 K (+136.02 %) |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Payment of Exercise | F | 238.26 | 201 | 47,890 | 1,127 | 1.3 K to 1.1 K (-15.14 %) |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 0.00 | 680 | 0 | 1,328 | 648 to 1.3 K (+104.94 %) |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Payment of Exercise | F | 238.26 | 62 | 14,772 | 648 | 710 to 648 (-8.73 %) |
| Feb 19 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 0.00 | 187 | 0 | 710 | 523 to 710 (+35.76 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Option Exercise | M | 0.00 | 283 | 0 | 1,594 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Option Exercise | M | 0.00 | 290 | 0 | 1,877 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 236.05 | 100 | 23,605 | 4,426 | 4.5 K to 4.4 K (-2.21 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 235.89 | 5 | 1,179 | 4,526 | 4.5 K to 4.5 K (-0.11 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 237.06 | 103 | 24,417 | 4,531 | 4.6 K to 4.5 K (-2.22 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Payment of Exercise | F | 238.26 | 78 | 18,584 | 4,634 | 4.7 K to 4.6 K (-1.66 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Buy | M | 0.00 | 283 | 0 | 4,712 | 4.4 K to 4.7 K (+6.39 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Payment of Exercise | F | 238.26 | 80 | 19,061 | 4,429 | 4.5 K to 4.4 K (-1.77 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Buy | M | 0.00 | 290 | 0 | 4,509 | 4.2 K to 4.5 K (+6.87 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 283 | 0 | 6,754 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 234 | 0 | 7,037 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 237.06 | 85 | 20,150 | 4,339 | 4.4 K to 4.3 K (-1.92 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 237.06 | 103 | 24,417 | 4,424 | 4.5 K to 4.4 K (-2.28 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 238.26 | 78 | 18,584 | 4,527 | 4.6 K to 4.5 K (-1.69 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 283 | 0 | 4,605 | 4.3 K to 4.6 K (+6.55 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 238.26 | 64 | 15,249 | 4,322 | 4.4 K to 4.3 K (-1.46 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 234 | 0 | 4,386 | 4.2 K to 4.4 K (+5.64 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 317 | 0 | 7,791 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 264 | 0 | 8,108 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 238.26 | 93 | 22,158 | 8,472 | 8.6 K to 8.5 K (-1.09 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 317 | 0 | 8,565 | 8.2 K to 8.6 K (+3.84 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 238.26 | 87 | 20,729 | 8,248 | 8.3 K to 8.2 K (-1.04 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 264 | 0 | 8,335 | 8.1 K to 8.3 K (+3.27 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 940 | 0 | 26,236 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 780 | 0 | 27,176 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 238.26 | 280 | 66,713 | 32,986 | 33.3 K to 33 K (-0.84 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 940 | 0 | 33,266 | 32.3 K to 33.3 K (+2.91 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 238.26 | 232 | 55,276 | 32,326 | 32.6 K to 32.3 K (-0.71 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 780 | 0 | 32,558 | 31.8 K to 32.6 K (+2.45 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 2,353 | 0 | 9,108 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 283 | 0 | 11,461 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 234 | 0 | 11,744 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 238.26 | 699 | 166,544 | 6,667 | 7.4 K to 6.7 K (-9.49 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 2,353 | 0 | 7,366 | 5 K to 7.4 K (+46.94 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 238.26 | 85 | 20,252 | 5,013 | 5.1 K to 5 K (-1.67 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 283 | 0 | 5,098 | 4.8 K to 5.1 K (+5.88 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 238.26 | 70 | 16,678 | 4,815 | 4.9 K to 4.8 K (-1.43 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 234 | 0 | 4,885 | 4.7 K to 4.9 K (+5.03 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Option Exercise | M | 0.00 | 353 | 0 | 4,345 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Option Exercise | M | 0.00 | 2,353 | 0 | 4,698 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Option Exercise | M | 0.00 | 234 | 0 | 7,051 | |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Payment of Exercise | F | 238.26 | 105 | 25,017 | 12,852 | 13 K to 12.9 K (-0.81 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Buy | M | 0.00 | 353 | 0 | 12,957 | 12.6 K to 13 K (+2.80 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Payment of Exercise | F | 238.26 | 699 | 166,544 | 12,604 | 13.3 K to 12.6 K (-5.25 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Buy | M | 0.00 | 2,353 | 0 | 13,303 | 11 K to 13.3 K (+21.49 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Payment of Exercise | F | 238.26 | 69 | 16,440 | 10,950 | 11 K to 11 K (-0.63 %) |
| Feb 17 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Buy | M | 0.00 | 234 | 0 | 11,019 | 10.8 K to 11 K (+2.17 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Schechter Adam H | President & CEO | Option Exercise | M | 0.00 | 3,506 | 0 | 19,348 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Schechter Adam H | President & CEO | Payment of Exercise | F | 223.78 | 1,028 | 230,046 | 11,288 | 12.3 K to 11.3 K (-8.35 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Schechter Adam H | President & CEO | Buy | M | 0.00 | 3,506 | 0 | 12,316 | 8.8 K to 12.3 K (+39.80 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 0.00 | 150 | 0 | 2,534 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Payment of Exercise | F | 223.78 | 53 | 11,860 | 523 | 576 to 523 (-9.20 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 0.00 | 150 | 0 | 576 | 426 to 576 (+35.21 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Option Exercise | M | 0.00 | 300 | 0 | 2,167 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 225.85 | 109 | 24,618 | 4,219 | 4.3 K to 4.2 K (-2.52 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Payment of Exercise | F | 223.78 | 83 | 18,574 | 4,328 | 4.4 K to 4.3 K (-1.88 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Buy | M | 0.00 | 300 | 0 | 4,411 | 4.1 K to 4.4 K (+7.30 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Summy Amy B. | EVP, Chief Marketin ... | Option Exercise | M | 0.00 | 266 | 0 | 2,534 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Summy Amy B. | EVP, Chief Marketin ... | Payment of Exercise | F | 223.78 | 94 | 21,035 | 172 | 266 to 172 (-35.34 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Summy Amy B. | EVP, Chief Marketin ... | Buy | M | 0.00 | 266 | 0 | 266 | 0 to 266 |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 560 | 0 | 7,271 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 225.85 | 203 | 45,848 | 4,152 | 4.4 K to 4.2 K (-4.66 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 223.78 | 154 | 34,462 | 4,355 | 4.5 K to 4.4 K (-3.42 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 560 | 0 | 4,509 | 3.9 K to 4.5 K (+14.18 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 560 | 0 | 8,372 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 223.78 | 187 | 41,847 | 8,071 | 8.3 K to 8.1 K (-2.26 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 560 | 0 | 8,258 | 7.7 K to 8.3 K (+7.27 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 970 | 0 | 27,956 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 223.78 | 306 | 68,477 | 31,778 | 32.1 K to 31.8 K (-0.95 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 970 | 0 | 32,084 | 31.1 K to 32.1 K (+3.12 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 560 | 0 | 11,978 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 223.78 | 190 | 42,518 | 4,651 | 4.8 K to 4.7 K (-3.92 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 560 | 0 | 4,841 | 4.3 K to 4.8 K (+13.08 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Option Exercise | M | 0.00 | 373 | 0 | 7,285 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Payment of Exercise | F | 223.78 | 131 | 29,315 | 10,785 | 10.9 K to 10.8 K (-1.20 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Buy | M | 0.00 | 373 | 0 | 10,916 | 10.5 K to 10.9 K (+3.54 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Seltz Judith C | EVP, CHRO | Option Exercise | M | 0.00 | 280 | 0 | 1,220 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Seltz Judith C | EVP, CHRO | Payment of Exercise | F | 223.78 | 96 | 21,483 | 915 | 1 K to 915 (-9.50 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Seltz Judith C | EVP, CHRO | Buy | M | 0.00 | 280 | 0 | 1,011 | 731 to 1 K (+38.30 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Payment of Exercise | F | 223.78 | 99 | 22,154 | 15,569 | 15.7 K to 15.6 K (-0.63 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Buy | M | 0.00 | 986 | 0 | 15,668 | 14.7 K to 15.7 K (+6.72 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Buy | M | 0.00 | 986 | 0 | 6,232 | 5.2 K to 6.2 K (+18.80 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Buy | M | 0.00 | 986 | 0 | 6,074 | 5.1 K to 6.1 K (+19.38 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Buy | M | 0.00 | 986 | 0 | 10,982 | 10 K to 11 K (+9.86 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Buy | M | 0.00 | 986 | 0 | 9,438 | 8.5 K to 9.4 K (+11.67 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Buy | M | 0.00 | 986 | 0 | 6,752 | 5.8 K to 6.8 K (+17.10 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Davis Jeffrey A. | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | Davis Jeffrey A. | Director | Buy | M | 0.00 | 986 | 0 | 1,159 | 173 to 1.2 K (+569.94 %) |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Option Exercise | M | 0.00 | 986 | 0 | 771 | |
| Feb 08 2021 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Buy | M | 0.00 | 986 | 0 | 19,880 | 18.9 K to 19.9 K (+5.22 %) |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | A | 233.39 | 8,000 | 1,867,120 | 8,000 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | A | 0.00 | 2,300 | 0 | 28,926 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Option Exercise | A | 233.39 | 2,500 | 583,475 | 2,500 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Option Exercise | A | 0.00 | 710 | 0 | 2,467 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Schechter Adam H | President & CEO | Option Exercise | A | 233.39 | 29,000 | 6,768,310 | 29,000 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Schechter Adam H | President & CEO | Option Exercise | A | 0.00 | 8,320 | 0 | 22,854 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | A | 233.39 | 4,600 | 1,073,594 | 4,600 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | A | 0.00 | 1,330 | 0 | 12,538 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Option Exercise | A | 233.39 | 3,100 | 723,509 | 3,100 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Option Exercise | A | 0.00 | 890 | 0 | 7,658 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | A | 233.39 | 4,600 | 1,073,594 | 4,600 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | A | 0.00 | 1,330 | 0 | 8,932 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | A | 233.39 | 4,600 | 1,073,594 | 4,600 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | A | 0.00 | 1,330 | 0 | 7,831 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Seltz Judith C | EVP, CHRO | Option Exercise | A | 233.39 | 2,300 | 536,797 | 2,300 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Seltz Judith C | EVP, CHRO | Option Exercise | A | 0.00 | 660 | 0 | 1,500 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Summy Amy B. | EVP, Chief Marketin ... | Option Exercise | A | 233.39 | 2,300 | 536,797 | 2,300 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Summy Amy B. | EVP, Chief Marketin ... | Option Exercise | A | 0.00 | 660 | 0 | 2,800 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | A | 233.39 | 1,200 | 280,068 | 1,200 | |
| Feb 04 2021 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | A | 0.00 | 350 | 0 | 2,684 |